Lysophosphatidylcholine Acyltransferase 1 (LPCAT1) Is Associated with the Progression of Prostatic Adenocarcinoma Independent of Race and Age.
Thomas J Lawrence, Xinchun Zhou, Zhi He, Charles Pound, Steven A Bigler. The University of Mississippi Medical Center, Jackson
Background: There is not yet a satisfactory biomarker in predicting the progression of prostate cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a recently characterized enzyme that converts lysophosphatidylcholine into phosphatidylcholine. Increased LPCAT1 activity has been reported in adenocarcinomas of the colon and prostate (PCa). The current study is designed to determine if there is correlation of LPCAT1 expression with various clinical features of prostate cancer.
Design: Tissue micro arrays (TMA) were made from 183 selected prostatic tissues from 123 patients accessioned over the past 20 years at The University of Mississippi Medical Center and used for the immunohistochemistry (IHC) study of LPCAT1. A scoring system was created by a combination of percentage of positive cells and intensity of staining recorded as 0, 1, 2 or 3. All specimens were divided into 4 groups: benign, high grade prostatic intraepithelial neoplasia (HGPIN), primary PCa, and metastatic PCa. Primary PCa was further sub-grouped as low grade, intermediate grade, and high grade according to Gleason scores (2-6, 7, and 8-10, respectively). The IHC combined score was also analyzed in relation to patient age and race.
Results: One-way analysis of variance (ANOVA) showed statistically significant difference in staining scores among groups (p < 0.0001). The mean staining score was 3 in metastatic PCa group, which was significantly higher than that in primary PCa, HGPIN, and benign groups (2.15, 1.13, 1.45, respectively; p=0.001981, p<0.0000001, p<0.0000001, respectively). There was a significant increase in staining of primary PCa as compared to PIN (p=0.00243) and to benign (p =0.000381). ANOVA also showed statistically significant difference among grades of primary PCa (p<0.0001); however, this difference was significant only between high and low grade primary cancers (p=0.001206). Also, LPCAT1 IHC scores were higher in primary tumors from patients who subsequently developed metastasis than in patients not known to have developed metastasis over the follow-up period, and this difference was independent of Gleason score. The results suggested that IHC scores for LPCAT1 did not correlate with patient's age and race in this study cohort.
Conclusions: The results of this study suggest that LPCAT1 is associated with the progression of prostate cancer independent of age and race. Primary prostate adenocarcinoma with higher LPCAT1 staining score predicts risk of distant metastasis.
Category: Genitourinary (including renal tumors)
Monday, February 28, 2011 9:30 AM
Poster Session I Stowell-Orbison/Surgical Pathology/Autopsy Awards Poster Session # 97, Monday Morning